About us

SML Biopharm is the next generation vaccine
It's a research and development company

Company Overview

SML Biopharm Co., Ltd. is a pioneering company at the forefront of mRNA vaccine and therapeutic development. Established in 2021, we focus on next-generation cancer vaccines and treatments for various diseases, utilizing cutting-edge mRNA platforms and advanced lipid nanoparticle (LNP) drug delivery systems, which gained global attention during the COVID-19 pandemic.

Our leadership team consists of Key Opinion Leaders (KOLs) with over 30 years of experience in vaccine research, development, and commercialization, with extensive expertise in antibody and virus. With a strong foundation in licensing and research, SML Biopharm is dedicated to becoming a global leader in the mRNA-based vaccine and therapeutics field.

We have already achieved significant milestones, securing multiple patents for our proprietary mRNA expression platform and LNP delivery system. Additionally, we are advancing a robust pipeline targeting a wide range of diseases. Looking ahead, we aim to expand our technology to address rare and infectious diseases, remaining committed to promoting a healthier future for all.

History

Our big moments
  • 2021.09

    SML Biopharma Established
    (Faculty Startup in the Department of Biomedical Sciences at Catholic University of Korea)

  • 2021.12

    Company - Affiliated Research Laboratory Established at Catholic University of Korea
    Seed Funding from Samkwang Labtree Co. Ltd. Secured

  • 2022.01

    Venture Business Status Certified

  • 2022.06

    Series A Funding from Meritz Securities Secured

  • 2022.08

    New headquarter and In-House Research Center Established at M Cluster by Gwangmyeong Station

  • 2022.11

    Government Grant Selected (KDCA)
    SFTS Immune Candidate Non-clinical and Sample Production Condition Establishment

  • 2023.04

    Grant Selected Top 1000+ Next-Generation Startups
    (Ministry of SMEs and Startups)

  • 2023.06

    Government Grant Selected (KDCA)
    Preclinical Sample Production and Evaluation for Securing SFTS therapeutic candidate substance